Baxiva AG

Next generation glycoconjugate vaccines to fight E. coli

There are over 80000 deaths yearly in the United States alone that have urinary tract infections listed as the original source of infection. UTIs are one of the most common infections, and they cost the US healthcare system over 3 billion USD per year. There is no effective prevention of UTIs on the market, and the majority of UTIs are caused by the bacterium E. coli. At Baxiva, we are preventing UTIs using a next-generation vaccine. Our vaccine helps your body to recognize the outer surface of the bacteria, which serves as its invisibility cloak. By recognizing the bacteria, the immune system can now fight bacteria as soon as they try to invade the body. We are three founders: Giorgia Greter, Tim Keys, and Christoph Rutschmann, with a passion for developing the next generation of vaccines

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No milestones

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Website

Baxiva AG

Next generation glycoconjugate vaccines to fight E. coli

Headquarter:
Schlieren

Foundation Date:
June 2025

Technology:

  • Biotech

Sectors:

  • Biotech
  • Vaccines

Support received

  • Support venturekick